Scholar Rock Holding Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SRRK Nasdaq 2836 www.scholarrock.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Scholar Rock Holding Corporation

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) - Oct 8th, 2026 6:00 am
3 drug targets pharma is betting on next - Oct 2nd, 2026 7:00 am
FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals - Sep 28th, 2026 4:44 am
Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says - Sep 25th, 2026 10:35 am
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 21st, 2026 10:00 am
This week in charts: GSK’s China deals, the $300M IPO club and selling the news - Sep 18th, 2026 4:43 am
Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale? - Sep 16th, 2026 10:06 pm
Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions - Sep 15th, 2026 5:16 pm
Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says - Sep 15th, 2026 12:52 pm
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy - Sep 14th, 2026 8:30 pm
SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets - Sep 14th, 2026 2:30 pm
Scholar Rock's Early FDA Approval on Spinal Muscular Atrophy Drug Seen as 'Positive Surprise,' UBS Says - Sep 14th, 2026 10:17 am
Scholar Rock Shares Rise 9.1% After FDA Approves ISEMBYLD for Spinal Muscular Atrophy - Sep 14th, 2026 6:08 am
Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump - Sep 14th, 2026 5:41 am
Scholar Rock SMA drug approved by FDA - Sep 14th, 2026 3:00 am
Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours - Sep 11th, 2026 5:31 pm
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA) - Sep 11th, 2026 4:25 pm
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial - Sep 2nd, 2026 6:00 am
Scholar Rock to Present at Upcoming Investor Conferences - Aug 27th, 2026 6:00 am
Scholar Rock (SRRK) Stock Looks Stretched On Book Value But Strong On Returns - Aug 22nd, 2026 8:07 am